Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

Dr. Jerome Zeldis and Dr. Blythe Sather bring exceptional backgrounds in cell therapy and solid tumorsCAMBRIDGE, Mass., Jan.

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

Celgene has today confirmed that it will acquire Juno Therapeutics for $9 billion, and says the move will make it a leader in cell immunotherapy. The price is a significant premium on the $5.5 bn ...

To list the 10 Best Wide Moat Stocks to Invest In, we scanned through VanEck Morningstar Wide Moat ETF and some online ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Eli Lilly and Company has announced the appointment of Winselow Tucker as President and General Manager for Lilly India, ...

A new study led by researchers at Moffitt Cancer Center shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed. The study, published in ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Perhaps most notably, the investor fought for months against Bristol Myers Squibb’s $74 billion buyout of immunology and ...

Celgene's European leader Tuomo Pätsi talks to pharmaphorum about the firm's remarkable growth, which is set to continue thanks to myeloma blockbuster Revlimid and new psoriasis and psoriatic ...